Introduction {#acr23245-sec-0005}
============

Pain is a dominant and common feature of rheumatoid arthritis (RA) and a cause of both distress and decreased work capacity [1](#acr23245-bib-0001){ref-type="ref"}. In early disease, pain is usually related to inflammation and correlates well with disease activity [2](#acr23245-bib-0002){ref-type="ref"}. However, some patients continue to exhibit high levels of pain, even after adequate antirheumatic treatment. Thus, earlier data have shown that a subset of patients has significant pain persistence in low disease activity [3](#acr23245-bib-0003){ref-type="ref"}, [4](#acr23245-bib-0004){ref-type="ref"}. Moreover, remaining pain in early RA may also be common after good treatment responses [5](#acr23245-bib-0005){ref-type="ref"}, [6](#acr23245-bib-0006){ref-type="ref"}.Significance & InnovationsThis study is the first, to our knowledge, to examine the association between dietary intake of omega‐3 fatty acid and omega‐6 fatty acid and noninflammatory pain in a large group of patients with early rheumatoid arthritis.The results of this study suggest that dietary omega‐3 fatty acid may be associated with noninflammatory chronic pain in methotrexate‐treated patients with early rheumatoid arthritis.

Omega‐3 fatty acids (FAs) and omega‐6 FAs are polyunsaturated FAs that have been associated with inflammation. Earlier data suggest that omega‐3 FAs are antiinflammatory and can decrease disease activity in RA [7](#acr23245-bib-0007){ref-type="ref"}. Also, excessive intake of omega‐6 FA as well as increased omega‐6:omega‐3 FA ratio have been linked with proinflammatory properties in RA [8](#acr23245-bib-0008){ref-type="ref"}. Increased dietary intake of omega‐3 FA has been associated with decreased serum levels of tumor necrosis factor (TNF) and C‐reactive protein (CRP) in RA. Higher omega‐6 FA intake, on the other hand, has been associated with increased serum levels of interleukin 6 (IL‐6) and CRP in RA [9](#acr23245-bib-0009){ref-type="ref"}. Although evidence exists on reduced CRP level and erythrocyte sedimentation rate (ESR) with increased omega‐3 FA, there are still no clear results regarding the long‐term effect of omega‐3 FA on inflammatory parameters [10](#acr23245-bib-0010){ref-type="ref"}. Important derivatives of omega‐3 FA are resolvins, protectins, and lipoxins. These nonclassical eicosanoids have antiinflammatory properties, and resolvins have been linked with pain suppression in experimental models [11](#acr23245-bib-0011){ref-type="ref"}, [12](#acr23245-bib-0012){ref-type="ref"}. Based on these observations, we hypothesized that dietary intake of omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio may affect not only inflammatory mechanisms, but also pain in RA. Therefore, we sought to investigate potential associations between dietary intake of these FAs and different pain patterns after antirheumatic treatment in early RA.

Patients and methods {#acr23245-sec-0006}
====================

Study population {#acr23245-sec-0007}
----------------

This study included primarily 1,296 newly diagnosed RA patients (disease duration ≤12 months) from a population‐based prospective case--control study called Epidemiological Investigation of Rheumatoid Arthritis (EIRA). Controls from the general population had been matched by age, sex, and area of residence (n = 2,632). EIRA began in May 1996, and the study design has previously been described [13](#acr23245-bib-0013){ref-type="ref"}. EIRA has been linked to the Swedish Rheumatology Quality register to provide clinical data. Patients who had completed food frequency questionnaires (FFQs) at EIRA inclusion/baseline, and who had been on methotrexate (MTX) monotherapy for at least the first 3 months from baseline, were included. The inclusion period for this study was from October 2005 to March 2012. Patients who did not fully complete the FFQ, had other disease‐modifying antirheumatic drugs than MTX during the first 3 months, or had missing data on a visual analog scale (VAS) for pain and CRP level after 3 months, were excluded. After patient exclusion, 591 patients remained. An overview of the patient exclusions is shown in Figure [1](#acr23245-fig-0001){ref-type="fig"}.

![Overview of patient exclusions. EIRA = Epidemiological Investigation of Rheumatoid Arthritis; RA = rheumatoid arthritis; FFQ = food frequency questionnaire; DMARD = disease‐modifying antirheumatic drug; MTX = methotrexate; VAS = visual analog scale; CRP = C‐reactive protein.](ACR-70-205-g001){#acr23245-fig-0001}

Dietary assessment {#acr23245-sec-0008}
------------------

Patients were asked to complete an FFQ at baseline regarding their food intake and habits. This specific self‐administered, semiquantitative FFQ included questions regarding patients' frequency intake of 123 food items and beverages during the previous year from baseline. Frequency food intake ranged over 8 categories from never to ≥3 times per day. Furthermore, information on portion size (i.e., small, medium, large) or quantity (i.e., slice, cup, glass, deciliter) of frequently consumed food items in Sweden was obtained. Dietary nutrient intakes (grams/day) of omega‐3 FA (FA C18:3/10 + FA C20:5 + FA C22:5 + FA C22:6) [14](#acr23245-bib-0014){ref-type="ref"}, [15](#acr23245-bib-0015){ref-type="ref"} and omega‐6 FA (FA C18:2 + FA C20:4) were calculated by multiplying the average frequency of consumption of each food item by the nutrient content, obtained from the Swedish National Food Administration Database [16](#acr23245-bib-0016){ref-type="ref"}. All dietary nutrients were energy adjusted using the residual method [17](#acr23245-bib-0017){ref-type="ref"}. This dietary assessment method and the validation of this FFQ have been described previously [18](#acr23245-bib-0018){ref-type="ref"}, [19](#acr23245-bib-0019){ref-type="ref"}. The FFQ also included questions regarding patients' supplement use of omega‐3 FA/fish oil.

Definition of pain outcome {#acr23245-sec-0009}
--------------------------

Pain in the previous week was assessed according to a VAS (range 0--100 mm) at baseline and at 3 months of treatment. Information on pain assessment was retrieved from the Swedish Rheumatology Quality register. Patient acceptable symptom state (PASS) is a validated measure that indicates the level of acceptable pain, among other clinical measures [20](#acr23245-bib-0020){ref-type="ref"}. PASS uses a threshold of VAS 40 mm, meaning that VAS \>40 mm indicates unacceptable pain. Based on PASS, we defined a new outcome, refractory pain, which indicates pain in spite of inflammatory control. Refractory pain was defined as VAS pain \>40 mm and CRP level \<10 mg/liter [21](#acr23245-bib-0021){ref-type="ref"} after antirheumatic treatment. In addition, inflammatory pain after treatment was defined as VAS pain \>40 mm and CRP level \>10 mg/liter. As a control group for refractory pain and inflammatory pain, we included patients with VAS pain \<40 mm together with CRP level \<10 mg/liter on the same visit as mentioned above. An overview of each defined pain group is presented in Figure [2](#acr23245-fig-0002){ref-type="fig"}.

![Definition of pain groups. PASS = patient acceptable symptom state; VAS = visual analog scale; CRP = C‐reactive protein.](ACR-70-205-g002){#acr23245-fig-0002}

Demographic and lifestyle variables {#acr23245-sec-0010}
-----------------------------------

Data on age, smoking, weight and height, education level, and physical activity were obtained through the EIRA questionnaire. Patients were asked to report their smoking habit. Smoking status was categorized as current, occasional, former, and never smoker, and smoking intensity was based on pack‐years; 1 pack‐year was equal to 20 smoked cigarettes, cigars, and/or pipes per day during 1 year. Body mass index (BMI) was calculated based on weight (kg) and height (m) as kg/m^2^. Education level was categorized into high school degree and university degree. Patients were asked to report the level of physical activity that they performed during the previous year from baseline, based on 4 categories, ranging from low to high physical activity: sedentary physical activity, occasional moderate physical activity, regular moderate physical activity, and regular exercise. Disease activity levels were based on the 28‐joint Disease Activity Score (DAS28) and were classified according to the definition of the European League Against Rheumatism (EULAR) [22](#acr23245-bib-0022){ref-type="ref"}.

Statistical analysis {#acr23245-sec-0011}
--------------------

Statistical analysis was performed with SPSS statistics software, version 23. Baseline characteristics and dietary intake between subgroups were compared with the Mann‐Whitney U test for continuous variables (mean ± SD) as well as Pearson\'s chi‐square test for proportions (%). Associations between dietary intake of omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio and unacceptable pain, refractory pain, and inflammatory pain were analyzed with logistic regression. In addition, associations between dietary omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio and inflammatory parameters, such as CRP level, ESR, swollen joint count (SJC), and DAS28 after 3 months, were studied in sensitivity analyses. All analyses were adjusted for potential confounders such as age, sex, smoking intensity, total energy intake, omega‐3 FA/fish oil supplementation, BMI, education, and physical activity. Dietary intake of omega‐3 FA and omega‐6 FA, and the omega‐6:omega‐3 FA ratio, were divided into tertiles based on the intake of the total EIRA sample, including matched controls; the first tertile was defined as referent group. Demographics and lifestyle variables were categorized as: age into 11 age groups with a 5‐year range for each, BMI into \<25 and \>25 kg/m², education into high school degree and university degree, physical activity level into either sedentary to occasional moderate physical activity, or regular moderate physical activity to regular exercise, total energy intake into tertiles, and supplementation of omega‐3 FA/fish oil into yes and no. Smoking adjustment was based on pack‐years. All levels of significance were set at 0.05.

Results {#acr23245-sec-0012}
=======

Patient characteristics {#acr23245-sec-0013}
-----------------------

This study included 591 RA patients. Baseline characteristics are presented in Table [1](#acr23245-tbl-0001){ref-type="table-wrap"}. Overall, the disease activity of the participants was high at baseline, with a mean DAS28 of 5.2. Of the total study sample, 30.8% were smokers, 24.0% had obtained a university degree, and 31.6% performed regular physical activity or regular exercise.

###### 

Baseline characteristics (n = 591)[a](#acr23245-note-0002){ref-type="fn"}

  Characteristics                                    Total
  -------------------------------------------------- -----------------------
  Female, %                                          70.6
  Age, years                                         52.8 ± 13.0
  Body mass index, kg/m²                             25.8 ± 4.7
  Smoking status: never/former/current, %            33.0/35.9/30.8
  Symptom duration, days                             289.7 ± 390.6
  Rheumatoid factor positive, %                      65.3
  Anti--citrullinated protein antibody positive, %   67.9
  Disease Activity Score in 28‐joints                5.2 ± 1.3
  C‐reactive protein, mg/liter                       22.4 ± 27.2
  Erythrocyte sedimentation rate (0--100 mm)         32.0 ± 21.7
  HAQ visual analog scale (0--100 mm)                1.1 ± 0.6
  Pain visual analog scale (0--100 mm)               53.9 ± 24.7
  Physician\'s global assessment (5‐point scale)     2.2 ± 0.7
  Patients' global assessment (0--100 mm)            50.5 ± 24.4
  SJC, mean ± SD / median (IQR)                      9.3 ± 5.5 / 9 (5--12)
  TJC, mean ± SD / median (IQR)                      8.2 ± 5.9 / 7 (4--12)
  Methotrexate, %                                    100.0
  Glucocorticoids, %                                 59.1
  Cyclooxygenase‐1 inhibitor, %                      52.6
  Cyclooxygenase‐2 inhibitor, %                      1.7
  Omega‐3 fatty acid/fish oil supplementation, %     19.5
  Omega‐3 fatty acid intake, grams/day               0.7 ± 0.4
  Omega‐6 fatty acid intake, grams/day               7.6 ± 2.3
  Omega‐6:omega‐3 fatty acid ratio                   13.4 ± 7.2

Values are the mean ± SD unless indicated otherwise. HAQ = Health Assessment Questionnaire; SJC = swollen joint count; IQR = interquartile range; TJC = tender joint count.

John Wiley & Sons, Ltd

After 3 months of MTX treatment, 125 patients (21.2%) had unacceptable pain, of which 92 patients (15.6%) had refractory pain, and 33 patients (5.6%) had inflammatory pain. When comparing baseline characteristics between subgroups, patients with refractory pain, compared to the control group (n = 420), had significantly higher BMI (mean ± SD 26.5 ± 4.5 versus 25.3 ± 4.3; *P* = 0.013), DAS28 (mean ± SD 5.4 ± 1.4 versus 5.0 ± 1.3; *P* = 0.017), Health Assessment Questionnaire (HAQ) score (mean ± SD 1.3 ± 0.6 versus 1.0 ± 0.6; *P* \< 0.001), VAS pain (mean ± SD 61 ± 23 versus 51 ± 25; *P* \< 0.001), patient\'s global assessment score (mean ± SD 58 ± 21 versus 48 ± 25; *P* \< 0.001), and tender joint count (TJC) (mean ± SD 10 ± 6 versus 8 ± 6; *P* = 0.003) at baseline. Patients with refractory pain also had a significantly higher proportion of current smokers compared to the control group (42.4% and 30.9%, respectively; *P* = 0.009).

The mean ± SD energy intake of the total study sample was 1,956.6 ± 685.8 kcal/day and was normally distributed. The intake of omega‐3 FA and omega‐6 FA, and the omega‐6:omega‐3 FA ratio, for the whole study group was mean ± SD 0.7 ± 0.5 grams/day, 7.6 ± 2.3 grams/day, and 13.5 ± 7.2, respectively. Omega‐3 FA/fish oil supplementation was used by 19.5% of the patients. Omega‐3 FA intake was found to be lower in patients with refractory pain compared to those without refractory pain (mean ± SD 0.6 ± 0.3 versus 0.7 ± 0.4 grams/day; *P* = 0.006).

Association between dietary intake of polyunsaturated FAs and pain {#acr23245-sec-0014}
------------------------------------------------------------------

Omega‐3 FA was inversely associated with, and the omega‐6:omega‐3 FA ratio was directly associated with, unacceptable pain, after adjustment for age, sex, smoking, total energy intake, and omega‐3 FA/fish oil supplementation (odds ratio \[OR\] 0.57 \[95% confidence interval (95% CI) 0.35--0.95\] and OR 1.70 \[95% CI 1.03--2.82\], respectively). These associations were based on comparison between the 3rd and the 1st tertile. Additional adjustments for anti--citrullinated protein antibody, BMI, education, and physical activity did not change the ORs remarkably. Omega‐6 FA alone did not significantly associate with unacceptable pain (OR 1.27 \[95% CI 0.73--2.20\]). Similar results were seen when analyzing the association between omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio and refractory pain (OR 0.47 \[95% CI 0.26--0.84\], OR 1.57 \[95% CI 0.82--3.03\], and OR 2.33 \[95% CI 1.28--4.24\], respectively). In contrast, omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio did not associate with inflammatory pain (OR 1.07 \[95% CI 0.45--2.56\], OR 0.81 \[95% CI 0.32--2.07\], and OR 0.65 \[95% CI 0.26--1.62\], respectively) (Table [2](#acr23245-tbl-0002){ref-type="table-wrap"}). Furthermore, the prevalence of omega‐3 FA/fish oil supplementation did not differ significantly between patients with and without unacceptable pain, and no statistically significant association was observed between omega‐3 FA/fish oil supplementation and unacceptable pain, after adjustment for age, sex, smoking, total energy intake, and dietary intake of omega‐3 FA (OR 0.97 \[95% CI 0.58--1.64\]).

###### 

Association between dietary intakes of omega‐3, omega‐6, and omega‐6:omega‐3 FA ratio and pain after 3 months of MTX treatment (n = 591)[a](#acr23245-note-0003){ref-type="fn"}

  Polyunsaturated FA intake (grams/day)         No.   Unacceptable pain                                          Refractory pain                                            Inflammatory pain
  --------------------------------------------- ----- ---------------------------------------------------------- ---------------------------------------------------------- -------------------
  Omega‐3 FA, tertiles                                                                                                                                                      
  1st ≤0.48                                     206   1.00                                                       1.00                                                       1.00
  2nd 0.49--0.77                                186   0.67 (0.41--1.09)                                          0.65 (0.38--1.13)                                          0.78 (0.30--1.97)
  3rd ≥0.78                                     199   0.57 (0.35--0.95)[b](#acr23245-note-0004){ref-type="fn"}   0.47 (0.26--0.84)[b](#acr23245-note-0004){ref-type="fn"}   1.07 (0.45--2.56)
  *P* [c](#acr23245-note-0005){ref-type="fn"}   --    0.029                                                      0.011                                                      0.873
  Omega‐6 FA, tertiles                                                                                                                                                      
  1st ≤6.00                                     192   1.00                                                       1.00                                                       1.00
  2nd 6.01--8.19                                196   1.43 (0.85--2.38)                                          1.89 (1.03--3.45)[b](#acr23245-note-0004){ref-type="fn"}   0.79 (0.32--1.98)
  3rd ≥8.20                                     203   1.27 (0.73--2.20)                                          1.57 (0.82--3.03)                                          0.81 (0.32--2.07)
  *P* [c](#acr23245-note-0005){ref-type="fn"}   --    0.395                                                      0.175                                                      0.665
  Omega‐6:omega‐3 FA, tertiles                                                                                                                                              
  1st ≤9.74                                     202   1.00                                                       1.00                                                       1.00
  2nd 9.75--14.19                               191   1.07 (0.63--1.83)                                          1.31 (0.68--2.49)                                          0.63 (0.26--1.53)
  3rd ≥14.20                                    198   1.70 (1.03--2.82)[b](#acr23245-note-0004){ref-type="fn"}   2.33 (1.28--4.24)[b](#acr23245-note-0004){ref-type="fn"}   0.65 (0.26--1.62)
  *P* [c](#acr23245-note-0005){ref-type="fn"}   --    0.039                                                      0.006                                                      0.353

Values are the odds ratio (95% confidence interval) unless indicated otherwise, with adjustments for age, sex, smoking pack‐years, total energy intake, and omega‐3 FA/fish oil supplementation. Unacceptable pain: visual analog (VAS) pain \>40 mm. Refractory pain: VAS pain \>40 mm and C‐reactive protein (CRP) level \<10 mg/liter. Inflammatory pain: VAS pain \>40 mm and CRP level \>10 mg/liter. FA = fatty acids; MTX = methotrexate.

Statistically significant.

Comparison between 3rd and 1st tertiles.

John Wiley & Sons, Ltd

To test whether the low inflammatory state contributed in a major way to these results, we performed sensitivity analyses using inflammatory parameters. These analyses showed that dietary omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio did not significantly associate with either CRP level, ESR, SJC, or DAS28 after 3 months (Table [3](#acr23245-tbl-0003){ref-type="table-wrap"}). In addition, there was no significant association observed between use of omega‐3/fish oil supplements and any of the inflammatory markers, after adjustment for age, sex, smoking, total energy intake, and dietary intake of omega‐3 FA (OR 1.04 \[95% CI 0.56--1.94\] for CRP level, OR 1.15 \[95% CI 0.75--1.76\] for ESR, OR 1.20 \[95% CI 0.82--1.94\] for SJC, and OR 1.02 \[95% CI 0.67--1.56\] for DAS28).

###### 

Dietary intake of omega‐3, omega‐6, and omega‐6:omega‐3 FA ratio and their association with inflammatory parameters (CRP, ESR, SJC, and DAS28) after 3 months of MTX treatment[a](#acr23245-note-0006){ref-type="fn"}

  Polyunsaturated FA intake (grams/day)   No.   OR (95 % CI)        *P*
  --------------------------------------- ----- ------------------- -------
  CRP \>12.44 mg/liter (median)                                     
  Omega‐3 FA                              581   1.10 (0.73--1.65)   0.665
  Omega‐6 FA                              581   1.07 (0.68--1.66)   0.772
  Omega‐6:omega‐3 FA                      581   0.95 (0.68--1.43)   0.800
  ESR \>13.00 mm (median)                                           
  Omega‐3 FA                              561   0.97 (0.64--1.49)   0.904
  Omega‐6 FA                              561   0.94 (0.60--1.48)   0.798
  Omega‐6:omega‐3 FA                      561   0.85 (0.56--1.29)   0.446
  SJC \>1 swollen joint (median)                                    
  Omega‐3 FA                              579   0.92 (0.60--1.41)   0.694
  Omega‐6 FA                              579   0.86 (0.56--1.42)   0.640
  Omega‐6:omega‐3 FA                      579   0.93 (0.61--1.42)   0.743
  DAS28 \>3.2                                                       
  Omega‐3 FA                              559   0.70 (0.46--1.07)   0.096
  Omega‐6 FA                              559   1.11 (0.71--1.72)   0.654
  Omega‐6:omega‐3 FA                      559   1.24 (0.82--1.87)   0.317

odds ratio (OR) adjusted for age, sex, smoking pack‐years, total energy intake, and omega‐3 fatty acid (FA)/fish oil supplementation. Comparison between 3rd and 1st tertiles. CRP = C‐reactive protein; ESR = erythrocyte sedimentation rate; SJC = swollen joint count; DAS28 = 28‐joint Disease Activity Score; MTX = methotrexate; 95% CI = 95% confidence interval.

John Wiley & Sons, Ltd

Discussion {#acr23245-sec-0015}
==========

This study is to our knowledge the first to examine the association between dietary intake of polyunsaturated FAs and pain patterns in early RA patients. We found that higher intake of omega‐3 FA was inversely associated with both unacceptable pain and refractory pain. A higher omega‐6:omega‐3 FA ratio was directly associated with unacceptable pain and refractory pain. In contrast, neither omega‐3 FA, omega‐6 FA, nor the omega‐6:omega‐3 FA ratio were significantly associated with inflammatory pain or key inflammatory parameters at 3 months. These data suggest inflammatory independent associations between omega‐3 FA and the omega‐6:omega‐3 FA ratio and pain in early RA.

Pain is the most important symptom in RA and often brings the patient to health care for the first time. In earlier literature, there is a discrepancy between pain and inflammation in the course of RA. Lee et al [3](#acr23245-bib-0003){ref-type="ref"} showed in 2012 that DAS28 remission does not exclude the persistence of significant pain. Moreover, we have earlier shown that remaining pain is common in early RA despite antirheumatic treatment [6](#acr23245-bib-0006){ref-type="ref"}. In the present study, we sought to investigate the prevalence not only of inflammatory‐related pain, but also pain in spite of inflammatory control. Although pain reduction is expected after MTX initiation in a majority of early RA patients, our data showed that 15.6% of all the patients still experienced pain after 3 months, in spite of low inflammation (refractory pain). A high frequency of significant pain after antirheumatic treatment is supported by other reports in the literature. For example, Andersson et al [23](#acr23245-bib-0023){ref-type="ref"} reported chronic widespread pain in over one‐third of patients with established RA. Moreover, there are several reports of higher prevalence of fibromyalgia in patients with RA compared to the general population [24](#acr23245-bib-0024){ref-type="ref"}. Widespread pain is common in RA and has been associated with high levels of pain, fatigue, and sleep problems [25](#acr23245-bib-0025){ref-type="ref"}, especially during the first year after RA diagnosis [26](#acr23245-bib-0026){ref-type="ref"}. Diagnosis of fibromyalgia was not in the scope of the present report, but the comparably high prevalence of refractory pain after 3 months is indicative that pain in spite of inflammation is a significant problem in early RA, thus, immunosuppressive therapy is not likely to have further major effects on decreasing pain. Patients with refractory pain had higher BMI, DAS28, HAQ score, VAS pain, patient\'s global assessment score, and TJC at baseline compared to the control group, and these results are in line with previous findings [6](#acr23245-bib-0006){ref-type="ref"}, [27](#acr23245-bib-0027){ref-type="ref"}. HAQ scores have been observed to be higher in RA patients with fibromyalgia [28](#acr23245-bib-0028){ref-type="ref"}. The patient\'s global assessment and TJC have also shown to strongly correlate with pain and DAS28 in RA patients [29](#acr23245-bib-0029){ref-type="ref"}, [30](#acr23245-bib-0030){ref-type="ref"}.

In this study, we used the well‐defined PASS for pain assessment, which was described earlier and validated as the level of definite unacceptable pain, the result of the question "If you were to remain for the rest of your life as you were during the last 48 hours, would that be acceptable or unacceptable for you?" However, PASS alone is a subjective measure, and therefore we considered an additional objective measure that could differentiate noninflammatory pain from inflammatory pain. Low inflammation was defined as a CRP level \<10 mg/liter. According to the American College of Rheumatology/EULAR definition of remission in RA, a CRP level of ≤10 mg/liter has been associated with low inflammatory RA core set measures, such as ESR, SJC, and DAS28, within the remission interval [21](#acr23245-bib-0021){ref-type="ref"}. Of note, there are also other assessments for noninflammatory pain described earlier in the literature. For instance, DAS28‐P, a modified DAS28 based on the patient\'s global assessment and TJC, has been used to measure noninflammatory pain in early RA [31](#acr23245-bib-0031){ref-type="ref"}. However, we did not consider DAS28‐P as appropriate for the current analysis, since we instead needed a dichotomous cutoff mirroring pain that the patient would find acceptable or unacceptable. Therefore, we instead used PASS in combination with low inflammation as stated above.

We investigated the dietary intake of polyunsaturated FAs in RA patients and its association with pain and inflammation. Omega‐3 FA and omega‐6 FA are essential nutrients and need to be obtained through diet or supplementation. These 2 FAs are distinguished based on the location of the first double bond, counting from the methyl end of the FA chain. As mentioned earlier, omega‐3 FA has been found to have antiinflammatory properties [7](#acr23245-bib-0007){ref-type="ref"}, [32](#acr23245-bib-0032){ref-type="ref"}, and omega‐6 FA has been linked to proinflammatory actions in RA [8](#acr23245-bib-0008){ref-type="ref"}. A diet rich in omega‐3 FA may have beneficial antiinflammatory effects for chronic diseases such as RA [32](#acr23245-bib-0032){ref-type="ref"}, but omega‐3 FA was not associated with high inflammation. This fact was illustrated by a trend towards negative association with DAS28 (OR 0.70; *P* = 0.096), which is in line with earlier data [7](#acr23245-bib-0007){ref-type="ref"}, [32](#acr23245-bib-0032){ref-type="ref"}. Earlier studies on clinical effects of omega‐3 FA supplementation in RA found primarily reduction of TJC and morning stiffness, and not peripheral inflammation to the same extent [7](#acr23245-bib-0007){ref-type="ref"}.

The results of this study may be interpreted as omega‐3 FA also having inflammation‐independent actions on pain. This interpretation was also supported by the lack of associations between omega‐3 FA and inflammatory parameters at the 3‐month followup, including inflammatory pain. In addition, omega‐3 FA has earlier been linked to the production of mediators involved in pain suppression. The latter include resolvins, protectins, and lipoxins, which are omega‐3 FA--derived nonclassical eicosanoids with antiinflammatory properties. Interestingly, resolvins (e.g., RvE1, RvD1) have been shown to directly suppress pain in experimental models [11](#acr23245-bib-0011){ref-type="ref"}, [12](#acr23245-bib-0012){ref-type="ref"}. These effects are mediated through inhibition of the actions of transient receptor potential cation (TRP) channels, such as TRPV1 and TRPA1 [16](#acr23245-bib-0016){ref-type="ref"}, both known to be strongly implicated in nociceptive mechanisms [33](#acr23245-bib-0033){ref-type="ref"}, [34](#acr23245-bib-0034){ref-type="ref"}. Based on the direct effects of RvD on nociceptive mechanisms, we might hypothesize that higher levels and activity of these mediators, related to an increased intake of omega‐3 FA, may result in direct effects on pain perception, although the exact clinical mechanisms need to be further explored. Potential neuroprotective actions of omega‐3 FA are further supported by earlier reports that omega‐3 FA can decrease neuroinflammation in animal models [35](#acr23245-bib-0035){ref-type="ref"}. Notably, RvD1 has also been found to have pro‐resolving and cartilage protective actions in inflammatory arthritis [36](#acr23245-bib-0036){ref-type="ref"}, and resolvins may also inhibit the production of proinflammatory omega‐6 FA--derived eicosanoids [37](#acr23245-bib-0037){ref-type="ref"}, leading to inflammation resolution. Another potential explanation for omega‐3 FA effects on pain in RA may be the interaction with microbiota in the gut. Omega‐3 FA supplementation was earlier shown to affect the gut microbiome in rodents [38](#acr23245-bib-0038){ref-type="ref"}, and intervention with gut microbiome regulation has been shown to affect neurodevelopment, also with potential effects on nociceptive mechanisms [39](#acr23245-bib-0039){ref-type="ref"}.

Earlier literature shows that a low ratio between omega‐6 FA and omega‐3 FA (recommended ratio range 1:1--4:1) needs to be maintained in order to avoid trigger of inflammation [40](#acr23245-bib-0040){ref-type="ref"}. In the present study, omega‐6 FA alone was not associated with unacceptable pain or refractory pain, but omega‐6:omega‐3 FA ratio was significantly associated with increased risk of unacceptable pain and refractory pain. A high omega‐6:omega‐3 FA ratio increases the risk for obesity [41](#acr23245-bib-0041){ref-type="ref"}, and high BMI has been associated both with high disease severity and pain in RA [42](#acr23245-bib-0042){ref-type="ref"}. Thus, obese RA patients were shown to have increased pain levels. In our study, associations between BMI, DAS28, and ESR and unacceptable pain and refractory pain were also confirmed (results not shown). Therefore, we adjusted the results for BMI, but with remaining associations between FA and refractory pain. Thus, the association between these polyunsaturated FAs and refractory pain seems to be independent of the BMI of the early RA patients in this context.

There are contradictory results regarding the benefits of omega‐3 FA supplementation. Several studies have shown that omega‐3 FA supplementation lowers inflammatory markers such as CRP, IL‐6, and TNF levels [43](#acr23245-bib-0043){ref-type="ref"}. In addition, cod liver oil supplements containing omega‐3 FA can be used as a sparing agent of nonsteroidal antiinflammatory drugs in RA patients [44](#acr23245-bib-0044){ref-type="ref"}, [45](#acr23245-bib-0045){ref-type="ref"}. Other results have not shown a superior clinical effect of omega‐3 FA supplementation [46](#acr23245-bib-0046){ref-type="ref"}. In our study, we found no association between use of omega‐3 FA/fish oil supplementation and refractory pain or inflammatory parameters. Thus, our data on potential protective effects of omega‐3 FA on pain should not be interpreted as showing that supplementation can be used therapeutically to reduce pain.

Regular physical activity before the onset of RA has been associated with reduced disease severity and pain [47](#acr23245-bib-0047){ref-type="ref"}. Moreover, patients with higher physical activity may have a different diet than other patients, and this diet could be composed of higher content of omega‐3 FA. However, when we stratified for physical activity in the present study, our results showed that physical activity levels did not differ between patients with refractory pain and the control group. In addition, further adjustment for physical activity in our main analyses did not change the ORs markedly.

Dietary data from FFQs were based on estimated dietary consumption. Recall bias as well as under‐ and overreporting may have occurred when completing the FFQ. Dietary patterns were assumed to be unchanged during the first 3 months from baseline. Clinical manifestations, treatment history, adherence, doses, and side effects of MTX from diagnosis were not considered in this study. Moreover, we had no data on depression or psychological factors, which are known to associate with self‐reported pain in RA [48](#acr23245-bib-0048){ref-type="ref"}. However, due to the registry‐based approach, we believe that the impact of depression on the current results should be limited. The VAS indicated overall pain and not disease‐related pain. In this study, refractory pain was defined as noninflammatory pain, but a CRP level \<10 mg/liter may still indicate some active inflammation.

In conclusion, omega‐3 FA was inversely, and the omega‐6:omega‐3 FA ratio was directly, associated with both unacceptable pain and refractory pain after 3 months of MTX treatment. These associations seemed to be independent of inflammation. A higher intake of omega‐3 FA may have reduced the central sensitization in patients in the control group. In addition, omega‐3 FA, omega‐6 FA, and the omega‐6:omega‐3 FA ratio did not associate with inflammatory pain nor with key inflammatory parameters after 3 months. Our data suggest that dietary omega‐3 FA may associate with noninflammatory chronic pain in MTX‐treated patients with early RA.
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